Noga Therapeutics is a gene therapy company focused on blood stem cell reprogramming to create transformative treatments for patients with severe and chronic illnesses. The company utilizes advanced lentiviral vector technology to reprogram blood stem cells, enabling targeted production of essential proteins within specific cells and tissues.
Noga’s therapeutic pipeline includes DopaGene for Parkinson’s disease, a novel gene therapy that induces sustained dopamine production in the brain. Additionally, the company is advancing treatments for X-linked Agammaglobulinemia (XLA), lysosomal storage diseases, and inflammatory bowel disease (IBD), targeting multiple conditions with significant unmet medical needs. Through these approaches, Noga Therapeutics aims to deliver durable, cell-targeted solutions that redefine treatment possibilities for complex diseases.
